Get the Stockscreener App
2.29
1.78%
0.04
Pre-market:
2.30
0.010
+0.44%
Gri Bio Inc stock is traded at $2.29, with a volume of 29,538.
It is up +1.78% in the last 24 hours and up +12.81% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.25
Open:
$2.27
24h Volume:
29,538
Relative Volume:
0.37
Market Cap:
$4.06M
Revenue:
-
Net Income/Loss:
$-10.91M
P/E Ratio:
-0.0288
EPS:
-79.5513
Net Cash Flow:
$-12.14M
1W Performance:
+5.53%
1M Performance:
+12.81%
6M Performance:
-82.78%
1Y Performance:
-93.71%
1-Day Range:
$2.211
$2.33
1-Week Range:
$2.1141
$2.35
52-Week Range:
$1.97
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
2.29 | 4.06M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Q1 2026 Earnings: EPS Misses Estimates by 76% Amid Revenue AbsenceEarnings Revision Report - newsline.com
GRI Bio Inc. (GRI) Slips Over 5% as Stock Tests Key Support Near $1.90Median Line - newsline.com
GRI Q1 2026 Earnings: EPS Miss by 76% as Pre-Clinical Biotech Continues to Report No RevenueWeak Earnings Momentum - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses EstimatesLong-Term Guidance - newsline.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Stepped-Up R&D Spending - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 76%Dividend Increase Stocks - newsline.com
GRI Bio Inc. (GRI) Struggles Near Support Amid Mixed Technical SignalsVolume Gap - The Legal Advocate
GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key SupportWyckoff Spring - The Legal Advocate
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Faces HeadwindsEPS Consistency Score - The Legal Advocate
GRI Bio Inc. (GRI) Slides 7% as Shares Test Key Support at $1.96Relative Volume - Newser
GRI Bio (GRI) Q1 2026 Results Miss Estimates — EPS $-1.61 vs $-0.91Positive Surprise Momentum - Newser
GRI Bio CEO to discuss innovative immune therapies at healthcare showcase May 20 - Pluang
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase - GlobeNewswire
Number of shareholders of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio (GRI) Falls -5.56% — Watching $1.94 Support 2026-05-15Sector Rotation - Newser
GRI Bio Reports Positive Phase 2a Results for GRI-0621 in IPF and Advances Immune-Modulating Pipeline with Strong Q1 2026 Financials - Minichart
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook - TipRanks
GRI Bio reports phase 2a data for IPF drug candidate GRI-0621 - Investing.com
GRI Bio Q1 net loss narrows on lower R&D expenses - TradingView
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
GRI Bio Reports First Quarter 2026 Financial Results, New - GlobeNewswire
H.C. Wainwright Maintains GRI Bio(GRI.US) With Buy Rating, Maintains Target Price $10 - Moomoo
GRI BIO ($GRI) Releases Q1 2026 Earnings - Moomoo
GRI Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GRI Bio (GRI) Schedule 13G/A: 90,475 shares represent 5.9% stake - Stock Titan
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GRI Bio (NASDAQ: GRI) Q1 loss narrows as cash runway extends into 2027 - Stock Titan
Is GRI Bio (GRI) stock hiding in plain sight? (+1.78%) 2026-05-11Low Volatility Stocks - Newser
GRI Stock Price, Quote & Chart | GRI BIO INC (NASDAQ:GRI) - ChartMill
GRI Bio (GRI) Stock: Is It a Good Portfolio Addition | Q4 2025: Earnings UnderperformReal Trader Insights - newser.com
GRI Bio announces 1-for-28 reverse share split - MSN
GRI Bio (GRI) Stock Consumer Data (-3.14%) 2026-04-24Oversold Bounce - Newser
GRI Bio (GRI) Stock Volume Drought (Tick Down) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Lào Cai
Market Valuation Insight | GRI Bio reports 294.6% EPS miss and zero revenueEarnings Trend Analysis - Newser
GRI | GRI Bio, Inc. Common Insider Trading - Quiver Quantitative
GRI Bio (GRI) Stock Volume Analysis (Grinds Higher) 2026-04-15Portfolio Ideas - UBND thành phố Hải Phòng
Is GRI Bio (GRI) Stock at a Peak | Price at $2.33, Down 4.90%Active ETF Flow - newsline.com
Revenue Check: What makes Friedman Industries Incorporated stock attractive today2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
GRI Bio (GRI) price target decreased by 75.16% to 163.20 - MSN
GRI Bio receives UAE patent for inflammatory disease treatment By Investing.com - Investing.com Australia
Big Picture: Can Euro Tech Holdings Company Limited continue delivering strong returns2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
GRI Springs on UAE Patent - Baystreet.ca
GRI Bio receives UAE patent for inflammatory disease treatment - Investing.com
GRI Bio Receives Notice of Allowance for UAE Patent - GlobeNewswire
GRI Bio lands UAE patent allowance for compounds targeting inflammation - Stock Titan
Sentiment Review: Is GRI Bio Inc forming a bullish divergence2026 Snapshot & Capital Efficiency Focused Ideas - baoquankhu1.vn
Aug Movers: Is GRI Bio Inc forming a bullish divergence2026 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionAditxt (NASDAQ:ADTX), Advanced Biomed (NAS - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Options Flow: Is GRI Bio Inc forming a double bottom2026 Weekly Recap & Stepwise Trade Execution Plans - baoquankhu1.vn
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):